Table 5.
Additional FDG PET/CT was performed in 8 patients within 1 week after CXCR4-targeted PET
Patient # | Age | Type | Grade | SUVmax CXCR4 | SUVmax FDG |
---|---|---|---|---|---|
2 | 58 | Primary cancer | G3 | 4.5 | 10.1 |
8 | 69 | Primary cancer | G2 | 3.2 | 16.5 |
9 | 50 | Primary cancer | G2 | 4.5 | 9.7 |
11 | 40 | Primary cancer | G2 | 1.8 | 2.6 |
14 | 62 | Nodal recurrence | G2 | 4.5 | 17.5 |
15 | 67 | Nodal recurrence | G3 | 4.0 | 24.4 |
17 | 71 | CUP | G2 | 4.5 | 33.0 |
18 | 71 | Nodal recurrence | G2 | 2.0 | 16.1 |
SUVmax obtained after 18F-FDG PET was higher in all examined cases compared to CXCR4-targeted PET